natgillin/translations-raw huggingface dataset:
Patients experiencing dizziness, fatigue, visual impairment or other undesirable effects with a potential impact on the ability to drive or use machines safely should refrain from these activities as long as the undesirable effects persist (see section 4.8).
Bolniki, pri katerih prihaja do omotičnosti, utrujenosti, motenj vida ali drugih neželenih učinkov, ki bi lahko vplivali na sposobnost varne vožnje ali upravljanja s stroji, ne smejo opravljati teh dejavnosti, dokler neželeni učinki vztrajajo (glejte poglavje 4.8).
Patients experiencing dyspnoea at rest due to complications of advanced malignancy and comorbidities may be at increased risk of a fatal ARR.
Pri bolnikih, ki imajo dispnejo v mirovanju zaradi komplikacij napredovale maligne bolezni in soobolenja, obstaja večje tveganje za reakcije, povezane z aplikacijo, s smrtnim izidom.
Patients experiencing infusion reactions should be advised not to drive and use machines until symptoms abate.
Bolnikom, pri katerih se pojavi infuzijska reakcija, je treba svetovati, naj ne vozijo ali upravljajo s stroji, dokler simptomi infuzijske reakcije ne izzvenijo.
Patients experiencing infusion-related reactions should be advised not to drive and use machines until symptoms abate.
Bolnikom je treba naročiti, naj ne vozijo ali upravljajo s stroji, če se jim pojavijo z infundiranjem povezane reakcije, dokler simptomi ne minejo.
Patients experiencing mild or moderate infusion-associated reactions when treated with agalsidase beta during clinical trials have continued therapy after a reduction in the infusion rate (~0.15 mg/min; 10 mg/hr) and/or pre-treatment with antihistamines, paracetamol, ibuprofen and/or corticosteroids.
Bolniki, ki so bili med kliničnimi preskušanji zdravljeni z agalzidazo beta in so imeli blage do zmerne reakcije, povezane z infuzijo, so zdravljenje nadaljevali po zmanjšanju hitrosti infundiranja (~0,15 mg/min; 10 mg/uro) in/ali predhodnem zdravljenju z antihistaminiki, paracetamolom, ibuprofenom in/ali kortikosteroidi.
Patients experiencing new or worsening peripheral neuropathy should undergo neurological evaluation and may require a change in the dose, schedule or route of administration to subcutaneous (see section 4.2).
Pri bolnikih, pri katerih se periferna nevropatija pojavi prvič ali se obstoječa periferna nevropatija poslabša, je treba napraviti nevrološko oceno in po potrebi prilagoditi odmerek ali shemo odmerjanja (glejte poglavje 4.2).
Patients experiencing pain during and after patch application should be provided with supportive treatment such as local cooling or oral analgesics (i.e. short acting opioids).
Bolnikom, ki imajo bolečine med nameščanjem in po nameščanju obliža, je treba zagotoviti podporno zdravljenje, na primer lokalno hlajenje ali peroralne analgetike (tj. kratkodelujoče opioide).
Patients experiencing rash during the 14-day lead-in period of 200 mg/day should not initiate treatment with Viramune prolonged-release tablets until the rash has resolved.
Bolnikom, pri katerih se med 14-dnevnim uvajalnim obdobjem pojavi izpuščaj, ne smejo začeti zdravljenja s zdravila viramune tablete s podaljšanim sproščanjem, dokler izpuščaj ne izgine.
Patients experiencing rash during the 14-day lead-in period should not initiate treatment with Viramune prolonged-release tablets until the rash has resolved.
Bolnikom, pri katerih se med 14-dnevnim uvajalnim obdobjem pojavi izpuščaj, ne smejo začeti zdravljenja z zdravilom Viramune tablete s podaljšanim sproščanjem, dokler izpuščaj ne izgine.
Patients experiencing skin reactions should be encouraged to avoid exposure to sunlight and apply broad spectrum sunscreens with a Sun Protection Factor (SPF)  30.
Bolniki, ki se jim pojavijo kožne reakcije, je treba naročiti, naj se ne izpostavljajo sončni svetlobi in naj uporabljajo širokospektralna sredstva za zaščito pred soncem z zaščitnim faktorjem (SPF)  30.
Patients experiencing these adverse reactions should not drive or use machines.
Bolniki, pri katerih se pojavijo ti neželeni učinki, ne smejo voziti ali upravljati s stroji.
Patients experiencing xerostomia are advised to drink water to moisten the buccal cavity prior to administration of Effentora.
Bolnikom, ki imajo kserostomijo, se svetuje, da pred uporabo zdravila Effentora spijejo vodo, da si ovlažijo ustno votlino.
Patients exposed only to antiretrovirals in utero or intrapartum were considered treatment-naive.
Bolniki, ki so bilo protiretrovirusnim zdravilom izpostavljeni le in utero ali med porodom, so bili obravnavani kot predhodno nezdravljeni.
Patients exposed to Plegridy every 2 weeks showed statistically significant reductions compared to patients exposed to Plegridy every 4 weeks over 2 years in a post-hoc analysis for endpoints including ARR (24%, p=0.0209), the risk of relapse (24%, p=0.0212), the risk of disability progression with 24 week confirmation (36%, p=0.0459), and MRI endpoints (new/enlarging T2 60%, Gd+ 71%, and new T1 hypointense lesions 53%; p<0.0001 for all).
Pri bolnikih, ki so bili 2 leti izpostavljenih zdravilu Plegridy vsaka 2 tedna, je prišlo do statistično značilnih zmanjšanj v primerjavi z bolniki, ki so bili zdravilu Plegridy izpostavljeni vsake 4 tedne, kot je pokazala analiza post-hoc za opazovane dogodke, vključno z ARR (24 %, p = 0,0209), tveganjem za recidiv (24 %, p = 0,0212), tveganjem za napredovanje bolezni s potrditvijo v 24. tednu (36 %, p = 0,0459) in opazovanim dogodki z MRS (nove/povečane T2 60 %, Gd+ 71 % in nove hipointenzivne lezije T1 53 %; p < 0,0001 za vse).
Patients following elective hip replacement surgery
Bolniki po operativni vstavitvi umetnega kolka
Patients following elective knee replacement surgery
Bolniki po operativni vstavitvi umetnega kolena
patients from 6 years of age who have beta thalassaemia major (an inherited blood disorder in which patients do not have enough normal haemoglobin in the blood) and who receive frequent blood transfusions;
bolnikih od šestega leta starosti dalje, ki imajo beta talasemijo major (dedno krvno bolezen, pri kateri bolniki nimajo dovolj normalnega hemoglobina v krvi) in ki prejemajo pogoste transfuzije krvi;
Patients from birth to <2 months of age
Bolniki od rojstva do < 2 meseca starosti
Patients from studies UC-I and UC-II had the option to roll over into an open-label long-term extension study (UC III).
Bolniki iz študij UC-I in UC-II so imeli možnost nadaljevati v odprti, dolgoročni podaljšani študiji (UC-III).
Patients from the age of 12 must take the content of one jar for one test.
Bolniki od 12 let naprej pri enem testnem postopku vzamejo vsebino enega lončka.
Patients from the age of 12 must take the contents of 1 jar with 75 mg.
Bolniki, stari 12 let ali več, morajo vzeti vsebino enega 75-miligramskega lončka.
Patients from the age of 2 years
Bolniki od 2. leta starosti
Patients from the group treated with epoetin alfa were also enrolled in an open-label extension study which demonstrated improvements in their quality of life that were maintained for an additional 12 months.
V odprti podaljšek študije, ki je pokazal izboljšanje kakovosti življenja, ki se je ohranilo dodatnih 12 mesecev, so bili vključeni tudi bolniki iz skupine, zdravljenje z epoetinom alfa.
Patients from the randomised trial were converted to perampanel over 16 weeks followed by a long term maintenance period (≥1 year).
Bolniki iz randomiziranih preskušanj so prešli na perampanel v 16-tedenskem obdobju, ki mu je sledilo dolgo vzdrževalno obdobje (≥ 1 leto).
Patients gaining ≥ 7 %, ≥ 15 % and ≥ 25 % of their baseline body weight with long-term exposure (at least 48 weeks) were very common (64.4 %, 31.7 % and 12.3 % respectively).
Zvečanje osnovne telesne mase za ≥ 25 % se je pri dolgoročni izpostavljenosti bolnikov (vsaj 48 tednov) pojavljalo zelo pogosto (v 64,4 %, 31,7 % in 12,3 %).
Patients gaining ≥ 7 %, ≥ 15 % and ≥ 25% of their baseline body weight with long-term exposure (at least 48 weeks) were very common (64.4 %, 31.7 % and 12.3 % respectively).
Zvečanje osnovne telesne mase za ≥ 7 %, ≥ 15 % in ≥ 25 % se je pri dolgoročni izpostavljenosti bolnikov (vsaj 48 tednov) pojavljalo zelo pogosto (v 64,4 %, 31,7 % in 12,3 %).
Patients gaining ≥7%, ≥15% and ≥25% of their baseline body weight with long-term- exposure (at least 48 weeks) were very common (64.4 %, 31.7 % and 12.3 % respectively).
Zvečanje osnovne telesne mase za ≥ 7 %, ≥ 15 % in ≥ 25 % se je pri dolgoročni izpostavljenosti bolnikov (vsaj 48 tednov) pojavljalo zelo pogosto (v 64,4 %, 31,7 % in 12,3 %).
Patients gaining ≥7%, ≥15% and ≥25% of their baseline body weight with long-term- exposure (at least 48 weeks) were very common (64.4 %, 31.7 % and 12.3 % respectively).
Zvečanje osnovne telesne mase za ≥ 7 %, ≥15 % in ≥ 25 % se je pri dolgoročni izpostavljenosti bolnikov (vsaj 48 tednov) pojavljalo zelo pogosto (v 64,4 %, 31,7 % in 12,3 %).
Patients given only ipilimumab lived for only 2.9 months without their disease getting worse.
Bolniki, ki so prejemali samo ipilimumab, so živeli samo 2,9 meseca brez poslabšanja bolezni.
Patients given Opdivo survived for around 25.0 months, compared with 19.6 months in patients given everolimus.
Bolniki, ki so prejemali Opdivo, so preživeli okoli 25,0 meseca, tisti, ki so prejemali everolimus, pa 19,6 meseca.
Patients given the combination lived longer on average, 25.6 months versus 18 months with vemurafenib.
Bolniki, ki so prejemali kombinacijo učinkovin, so povprečno živeli 25,6 meseca v primerjavi z 18 mesecev pri jemanju vemurafeniba.
Patients given the solution for infusion should be switched to Noxafil tablets or oral suspension as soon as the patient’s condition allows it.
Bolniki, ki prejemajo raztopino za infundiranje, morajo čim prej, ko njihovo stanje to omogoča, preiti na uživanje tablet ali peroralne suspenzije zdravila Noxafil.
Patients given Vectibix with FOLFIRI lived for an average of 14.8 months while patients given Vectibix with FOLFOX lived for an average of 12.8 months without their disease getting worse.
Bolniki, ki so prejemali zdravilo Vectibix skupaj s FOLFIRI, so v povprečju brez poslabšanja bolezni živeli 14,8 meseca, bolniki, ki so prejemali zdravilo Vectibix skupaj s kemoterapijo FOLFOX, pa v povprečju 12,8 meseca.
Patients given Xofigo also took longer for signs and symptoms of progressive disease such as fractures and bone pain to develop.
Pri bolnikih, ki so jim dajali zdravilo Xofigo, so se tudi kasneje pojavili znaki in simptomi napredovanja bolezni, kot so zlomi in bolečine v kosteh.
Patients had 5-20 typical visible or palpable AK lesions in an area that exceeded 25 cm2 on either the face or balding scalp.
Bolniki so imeli 5-20 klinično značilnih, vidnih ali otipljivih AK lezij na predelu, katerega površina je presegala 25 cm2, na obrazu ali neporaščenem lasišču.
Patients had a BMI 30 kg/m² or BMI>27 kg/m² with hypertension and/or dyslipidemia at inclusion.
Bolniki so imeli ITM <  30 kg/m2 ali ITM > 27 kg/m2 ter hipertenzijo in/ali dislipidemijo ob vključitvi.
Patients had a history of chronic non-cancer pain and were taking opioids with stable doses of at least 50 mg of oral morphine equivalents per day.
Bolniki so imeli anamnezo kronične bolečine, ki ni posledica raka, in so jemali stabilne odmerke opioidov, ki so ustrezali vsaj 50 mg peroralnega morfina na dan.
Patients had a mean age of 15 years (range 12-17), were 56% female, 12% Asian, and 88% Black.
Bolniki so imeli povprečno starost 15 let (razpon: 12–17) in 56 % je bilo žensk, 12 % Azijcev in 88 % črncev.
Patients had a mean age of 41 years (range 21-77), 89% were male, 67% were White, and 19% were Black.
Bolniki so bili povprečno stari 41 let (razpon 21–77), 89 % je bilo moških, 67 % je bilo belcev in 19 % je bilo črncev.
Patients had a mean age of 42 years (range 19-73), 88% were male, 77% were White, 17% were Black, and 17% were Hispanic/Latino.
Bolniki so bili povprečno stari 42 let (razpon 19–73), 88 % je bilo moških, 77 % je bilo belcev, 17 % je bilo črncev in 17 % jih je bilo španskega/latinskoameriškega porekla.
Patients had a mean age of 42 years (range 19-73), 88% were male, 77% were White, and 17% were Black.
Bolniki so bili povprečno stari 42 let (razpon 19–77), 88 % je bilo moških, 77 % je bilo belcev in 17 % je bilo črncev.
Patients had a median platelet count of 14 x 109/l at study entry.
Ob vključitvi v študijo so imeli bolniki mediano vrednost števila trombocitov 14 x 109/l.
Patients had a median platelet count of 19 x 109/l at study entry.
Ob vključitvi v študijo so imeli bolniki mediano vrednost števila trombocitov 19 x 109/l.
Patients had active SLE disease, defined as a SELENA-SLEDAI (SELENA=Safety of Estrogens in Systemic Lupus Erythematosus National Assessment; SLEDAI=Systemic Lupus Erythematosus Disease Activity Index) score 6 and positive anti-nuclear antibody (ANA) test results (ANA titre 1:80 and/or a positive anti-dsDNA [30 units/ml]) at screening.
Bolniki so imeli aktiven SLE; to je bilo opredeljeno kot rezultat SELENA-SLEDAI (SELENA = Safety of Estrogens in Systemic Lupus Erythematosus National Assessment, SLEDAI = Systemic Lupus Erythematosus Disease Activity Index)  6 in pozitiven izvid testa protijedrnih protiteles (ANA) (titer ANA  1:80 in/ali pozitiven anti-dvDNK [ 30 enot/ml]) ob presejanju.
Patients had been receiving opioid therapy for pain (median daily baseline oral morphine equivalent dose = 160 mg) and had opioid-induced constipation (<3 rescue medication-free bowel movements per week during the screening period).
Bolniki so imeli z opioidi povzročeno konstipacijo (< 3 iztrebljanja brez rešilnega odvajala na teden v obdobju presejanja).
Patients had clinically typical, visible, discrete, nonhyperkeratotic, nonhypertrophic AK lesions on the balding scalp or face within a contiguous 25 cm2 treatment area.
V obeh raziskavah so imeli bolniki klinično tipične, vidne, ločene, nehiperkeratotične, nehipertrofične lezije AK v neprekinjenem področju zdravljenja 25 cm2 na lasišču ali obrazu.
Patients had IgG/IgA/Light chain myeloma in 63%/25%/8% instances, a median hemoglobin of 105 g/l, and a median platelet count of 221.5 x 109/l.
Bolniki so imeli plazmocitom IgG/IgA/lahke verige v 63%/25%/8%, mediano koncentracijo hemoglobina 105 g/l in mediano število trombocitov 221,5 x109/l.
Patients had not received prior therapy for MS.
Bolniki predhodno niso bili zdravljeni za MS.
Patients had opioid-induced constipation (< 3 rescue medication-free bowel movements per week during the screening period).
Bolniki so imeli z opioidi povzročeno konstipacijo (< 3 iztrebljanja brez rešilnega odvajala na teden v obdobju presejanja).
Patients had primary pulmonary hypertension (10 patients) or pulmonary arterial hypertension related to congenital heart diseases (9 patients) and were in WHO functional class II (n = 15 patients, 79%) or class III (n = 4 patients, 21%) at baseline.
Bolniki so imeli primarno pljučno hipertenzijo (10 bolnikov) ali pljučno arterijsko hipertenzijo, povezano s prirojenimi boleznimi srca (9 bolnikov) in so bili po klasifikaciji Svetovne zdravstvene organizacije ob izhodišču razvrščeni v funkcijski razred II (n = 15 bolnikov, 79 %) ali razred III (n = 4 bolniki, 21%).
Patients had primary pulmonary hypertension (10 patients) or pulmonary arterial hypertension related to congenital heart diseases (9 patients) and were in WHO functional class II (n = 15 patients, 79%) or class III (n = 4 patients, 21%) at baseline.
Bolniki so imeli primarno pljučno hipertenzijo (10 bolnikov) ali pljučno arterijsko hipertenzijo, povezano s prirojenimi boleznimi srca (9 bolnikov) in so bili po klasifikaciji Svetovne zdravstvene organizacije ob izhodišču razvrščeni v funkcijski razred II (n = 15 bolnikov, 79 %) ali razred III (n = 4 bolniki, 21%). .
Patients had prior exposure to a median of 12 antiretrovirals for a median of 7 years.
Bolniki so bili predhodno izpostavljeni mediani 12 protiretrovirusnih zdravil za mediano obdobje 7 let.
Patients had received a median of 14 months of prior IFN therapy at doses ≥ 25 x 106 IU/week and were all in late chronic phase, with a median time from diagnosis of 32 months.
Povprečno trajanje predhodnega zdravljenja z IFN z odmerki ≥ 25 x 106 i.e./teden je bilo 14 mesecev, bolniki pa so bili vsi v pozni kronični fazi s povprečnim časom 32 mesecev od postavitve diagnoze.
Patients had received a median of 14 months of prior IFN therapy at doses  25 x 106 IU/week and were all in late chronic phase, with a median time from diagnosis of 32 months.
Povprečno trajanje predhodnega zdravljenja z IFN z odmerki  25 x 106 i.e./teden je bilo 14 mesecev, bolniki pa so bili vsi v pozni kronični fazi s povprečnim časom 32 mesecev od postavitve diagnoze.
Patients had serum samples tested for autoantibodies at multiple time points in rheumatoid arthritis Studies I−V.
V študijah revmatoidnega artritisa I−V so pri bolnikih ob več različnih časih testirali protitelesa v serumu.
Patients had serum samples tested for autoantibodies at multiple time points in rheumatoid arthritis Studies I−V.
V študijah revmatoidnega artritisa I−V so pri bolnikih so ob več različnih časih testirali protitelesa v serumu.
Patients had the opportunity to receive open-label aprepitant in subsequent cycles (Optional Cycles 2-6); however efficacy was not assessed in these optional cycles.
Bolniki so imeli možnost v naslednjih ciklusih (na izbiro od 2. do ciklusa) odprto prejemati aprepitant, vendar učinkovitosti v teh neobveznih ciklusih niso ocenili.
Patients had to have a Karnofsky Performance Score (KPS) 70%.
Bolniki so imeli oceno stanja telesne zmogljivosti po Karnofskem (KPS)  70 %.
Patients had to have been stably suppressed (HIV-1 RNA < 50 copies/mL) for at least 6 months prior to screening.
Bolniki so morali biti s stabilno supresijo (HIV-1 RNA < 50 kopij/ml) vsaj 6 mesecev pred presejanjem.
Patients had to have neutrophils >1,500/mm3, platelets >100,000/mm3, haemoglobin >10 g/dl, creatinine
Bolniki so morali imeti število nevtrofilcev > 1.500/mm3 in trombocitov > 100.000/mm3, hemoglobin > 10 g/dl, kreatinin < 1,5-kratno ZNM, celotni bilirubin
Patients had to have previously only received efavirenz/emtricitabine/tenofovir disoproxil as their first antiretroviral regimen for at least three months, and wished to switch regimens due to efavirenz intolerance.
Bolniki so morali predhodno vsaj tri mesece prejemati le efavirenz/emtricitabin/dizoproksiltenofovirijev fumarat kot svoj prvi protiretrovirusni režim za vsaj tri mesece in so želeli preiti na drug režim zaradi neprenašanja efavirenza.
Patients had undergone treatment with two or more regimens of platinum-based chemotherapy, and they had had a durable response (the cancer had not progressed for at least 6 months) before the last regimen.
Bolnice so prejele dve ali več shem kemoterapije na osnovi platine in so se pred zadnjo shemo nanjo trajno odzvale (rak ni napredoval vsaj 6 mesecev).
Patients have developed exfoliative cutaneous reactions, such as Stevens-Johnson syndrome, during treatment with VFEND.
Med zdravljenjem z zdravilom VFEND so se pri bolnikih pojavile eksfoliacijske kožne reakcije, kot na primer Stevens-Johnsonov sindrom.
Patients have developed exfoliative cutaneous reactions, such as Stevens-Johnson syndrome, during treatment with voriconazole.
Med zdravljenjem z vorikonazolom so se pri bolnikih pojavile eksfoliacijske kožne reakcije, kot na primer Stevens-Johnsonov sindrom.
Patients have developed serious cutaneous reactions, including Stevens-Johnson syndrome (uncommon), toxic epidermal necrolysis (rare) and erythema multiforme (rare) during treatment with VFEND.
Pri bolnikih so se med zdravljenjem z zdravilom VFEND pojavile hude kožne reakcije, vključno s Stevens-Johnsonovim sindromom (občasno), toksično epidermalno nekrolizo (redko) in multiformnim eritemom (redko).
Patients have developed serious cutaneous reactions, including Stevens-Johnson syndrome (uncommon), toxic epidermal necrolysis (rare) and erythema multiforme (rare) during treatment with voriconazole.
Pri bolnikih so se med zdravljenjem z vorikonazolom pojavile hude kožne reakcije, vključno s Stevens-Johnsonovim sindromom (občasno), toksično epidermalno nekrolizo (redko) in multiformnim eritemom (redko).
patients having “haemo-dialysis”- where a “dialysis” machine removes waste products from the blood patients who are going to have “haemo-dialysis” in the future.
bolnike na hemodializi, pri kateri naprava za dializo odstrani odpadne snovi iz krvi, bolnike, ki se bodo s hemodializo zdravili v prihodnje.
Patients homozygous for the UGT1A1*28 allele were given a lower initial dose of ONIVYDE (see section 4.2).
Bolniki s homozigotnostjo za alel UGT1A1*28 so prejeli manjši začetni odmerek zdravila ONIVYDE (glejte poglavje 4.2).
Patients hypersensitive to Insulin Human Winthrop Basal for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Bolniki, ki so preobčutljivi za Insulin Human Winthrop Basal, a tudi nobenega drugega pripravka ne prenašajo bolje, smejo zdravljenje nadaljevati le pod skrbnim zdravniškim nadzorom in – če je potrebno – ob hkratnem antialergijskem zdravljenju.
Patients hypersensitive to Insulin Human Winthrop Comb 15 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Bolniki, ki so preobčutljivi za Insulin Human Winthrop Comb 15, a tudi nobenega drugega pripravka ne prenašajo bolje, smejo zdravljenje nadaljevati le pod skrbnim zdravniškim nadzorom in – če je potrebno – ob hkratnem antialergijskem zdravljenju.
Patients hypersensitive to Insulin Human Winthrop Comb 25 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Bolniki, ki so preobčutljivi za Insulin Human Winthrop Comb 25, a tudi nobenega drugega pripravka ne prenašajo bolje, smejo zdravljenje nadaljevati le pod skrbnim zdravniškim nadzorom in – če je potrebno – ob hkratnem antialergijskem zdravljenju.
Patients hypersensitive to Insulin Human Winthrop Comb 30 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Bolniki, ki so preobčutljivi za Insulin Human Winthrop Comb 30, a tudi nobenega drugega pripravka ne prenašajo bolje, smejo zdravljenje nadaljevati le pod skrbnim zdravniškim nadzorom in – če je potrebno – ob hkratnem antialergijskem zdravljenju.
Patients hypersensitive to Insulin Human Winthrop Comb 50 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Bolniki, ki so preobčutljivi za Insulin Human Winthrop Comb 50, a tudi nobenega drugega pripravka ne prenašajo bolje, smejo zdravljenje nadaljevati le pod skrbnim zdravniškim nadzorom in – če je potrebno – ob hkratnem antialergijskem zdravljenju.
Patients hypersensitive to Insulin Human Winthrop Infusat for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Bolniki, ki so preobčutljivi za Insulin Human Winthrop Infusat, a tudi nobenega drugega pripravka ne prenašajo bolje, smejo zdravljenje nadaljevati le pod skrbnim zdravniškim nadzorom in – če je potrebno – ob hkratnem antialergijskem zdravljenju.
Patients hypersensitive to Insulin Human Winthrop Rapid for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Bolniki, ki so preobčutljivi za Insulin Human Winthrop Rapid, a tudi nobenega drugega pripravka ne prenašajo bolje, smejo zdravljenje nadaljevati le pod skrbnim zdravniškim nadzorom in – če je potrebno – ob hkratnem antialergijskem zdravljenju.